Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Amsterdam, The Netherlands - Online CME

Video navigation menu

How much Lp(a) lowering is required? 00:40
Effects of currently available lipid-lowering treatments on Lp(a) levels 01:50
RNA-based therapies and Lp(a) 05:09
What patients could potentially benefit from potent Lp(a) lowering? 07:44

Educational information

This lecture by prof. Erik Stroes was part of an accredited symposium "Lp(a): from CV risk marker to therapeutic target" held during the virtual ESC Congress 2021.

Faculty

Prof. Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Centers in Amsterdam, The Netherlands.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by unrestricted educational grants received from Sanofi and Novartis.

Click here for the meeting report View slides of this presentation

Online-CME

This is available as accredited online CME on coursepath for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.